Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia

[PR Newswire] – NORTH CHICAGO, Ill., Sept. 14, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food . . . → Read More: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia Similar Articles: Company Update (NYSE:ABBV): AbbVie to seek FDA approval for leukemia drug after trial success Stock Update (NYSE:ABBV): C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie’s Acquisition of Pharmacyclics